Related by context. All words. (Click for frequent words.) 79 Crohn Disease Activity 73 DAS# CRP 72 nasal symptom 71 YMRS 71 WOMAC pain 71 Index CDAI 71 IBDQ 71 Brief Psychiatric 71 subscale scores 70 Disease Activity 70 NIHSS 70 subscore 70 ADAS cog 70 Ocular Surface Disease 70 PANSS 70 HDRS 70 DAS# [002] 69 BMI z 69 CDAI score 69 Psoriasis Area 69 CDAI 69 Y BOCS 69 MADRS score 69 NYHA functional class 69 Health Assessment Questionnaire 69 WOMAC 69 MADRS 68 HAM D# 68 subscores 68 CHADS2 68 MMSE score 68 HAQ DI 68 APACHE II 68 Neuropsychiatric Inventory 68 symptom severity 68 EQ 5D 68 mRS 68 pain subscale 67 Severity Index PASI 67 Global Impression CGI 67 Brief Pain 67 Visual Analogue Scale VAS 67 Montgomery Åsberg Depression 67 clinically meaningful improvement 67 PANSS total 67 recurrent venous thromboembolism 67 EDSS score 67 ADAS Cog 67 IRLS score 67 Rating Scale MADRS 67 HOMA IR 67 erection hardness 67 Alzheimer Disease Assessment 67 Montgomery Asberg Depression 67 HAMD 67 Scale PANSS 67 bronchial hyperresponsiveness 67 Score DAS 66 SGRQ 66 International Prostate Symptom 66 PSQI 66 serologically active patients 66 subscales 66 tipranavir r 66 HRQoL 66 UPDRS 66 IRLS 66 Score DAS# 66 apnea hypopnea index 66 Scale EDSS 66 depressive symptom 66 ACR Pedi 66 Fibromyalgia Impact Questionnaire 65 HRQL 65 SELENA SLEDAI 65 Visual Analog 65 QIDS SR 65 depressive symptomatology 65 CFQ R 65 albumin excretion rate 65 Expanded Disability Status 65 HADS 65 salivary cortisol 65 Scale EDSS score 65 ADHD RS 65 urinary albumin 65 logistic regression model 65 Severity Index 65 apnea hypopnea 65 MetS 65 interrater reliability 65 regression coefficient 64 salmeterol fluticasone propionate 64 Score IPSS 64 neutropaenia 64 Primary endpoints 64 DLQI 64 mg BID dose 64 HbA 1c levels 64 TNSS 64 ADCS CGIC 64 Glasgow Coma Scale 64 NIHSS score 64 ADCS ADL 64 HAM D 64 treat NNT 64 CORE OM 64 Rating Scale BPRS 64 Visual Analog Scale 64 Stroke Scale 64 Negative Syndrome 64 antibody titer 64 p = .# [002] 64 UPDRS motor 64 liver histology 64 interobserver 64 Female Sexual Function 64 logistic regression analysis 64 baseline HbA1c 64 CI -#.# 64 Skin sterol 64 symptomatic VTE 64 HRQOL 64 Physical Component 64 Symptom severity 63 serum HCV RNA 63 % Confidence Interval 63 hours postdose 63 OSDI 63 Unified Parkinson Disease 63 erythrocyte sedimentation rate 63 Ejection Fraction 63 DAS# scores 63 anemia hemoglobin 63 mTSS 63 hemoglobin A1c HbA1c 63 FluCAM arm 63 multivariable adjusted 63 serum urate 63 Symptom Score 63 Stroke Scale NIHSS 63 ANCOVA 63 Distress Scale 63 colorectal adenoma 63 spirometric 63 Severity MSCS score 63 symptom exacerbation 63 serum HBV DNA 63 confidence intervals CIs 63 Status Scale EDSS 63 IPSS 63 variance ANOVA 63 oxycodone CR 63 Secondary endpoints included 63 CNS LS 63 serum cortisol 63 sd = 63 lowest tertile 63 urine albumin 63 odds ratios ORs 62 rhinoconjunctivitis 62 nonfatal MI 62 NNT = 62 elevated ALT 62 4mg/kg 62 MMSE 62 QoL 62 logistic regression analyzes 62 lopinavir r arm 62 SELENA SLEDAI score 62 Pain Intensity 62 PSA nadir 62 atheroma volume 62 morphometric vertebral fractures 62 Main Outcome Measure 62 BILAG 62 hip BMD 62 oxygen desaturation 62 SF #v# 62 ALT elevations 62 aspartate aminotransferase 62 QTcF 62 â ‰ ¥ 62 Clinician Administered PTSD 62 IIEF 62 Neuropsychiatric Inventory NPI 62 leukocyte count 62 ankle brachial 62 corticosteroid dose 62 Rating Scale UPDRS 62 multiple logistic regression 62 interobserver reliability 62 Inventory BPI 62 posttreatment 62 serum aminotransferase levels 62 lumbar spine BMD 62 Visual acuity 62 biopsy Gleason 62 preoperative PSA 62 Ishak fibrosis score 62 macroalbuminuria 62 BPRS 62 univariate analyzes 62 Epworth Sleepiness Scale 62 dyspnea 62 bivariate analyzes 62 Fasting plasma glucose 62 definite stent thrombosis 62 plasma cortisol 62 EORTC QLQ C# 62 methacholine challenge 62 methotrexate monotherapy 62 % CI #.#-#.# [007] 62 mcg QD 62 IELT 62 moderately emetogenic 62 Dyspnea 62 Scale cognitive subscale 62 fasting insulin 62 attain statistical significance 62 WAIS III 62 neurocognitive function 62 multivariate Cox 62 visceral adiposity 62 autonomic dysfunction 62 fructosamine 62 intravaginal ejaculatory latency 62 Pearson correlation coefficient 62 ACR# response 62 Cronbach alpha 62 severe exacerbations 62 ANOVA 62 recurrent VTE 61 alteplase 61 meta regression 61 Erectile Function 61 Secondary endpoints include 61 alanine aminotransferase 61 BPH Symptom Score 61 % CI #.#-#.# [006] 61 Hb A1C 61 LV dysfunction 61 Visual Analogue Scale 61 Depressive symptoms 61 HbA 1c 61 Functional Assessment 61 intraobserver 61 achieved statistical significance 61 Secondary endpoints 61 alanine aminotransferase ALT 61 cTnT levels 61 KOOS 61 % CI #.#-#.# [003] 61 p = #.# [003] 61 univariate 61 asthma exacerbation 61 concomitant medications 61 Insulin sensitivity 61 MMSE scores 61 timepoints 61 #mg/day [001] 61 FACIT Fatigue 61 HBeAg 61 abdominal pain abdominal discomfort 61 Hamilton Rating Scale 61 evaluable subjects 61 coronary stenosis 61 Score TOS 61 PASI scores 61 -#.# ± [002] 61 posttest 61 virological response 61 serum PSA 61 extrapyramidal symptoms 61 REYATAZ r arm 61 timepoint 61 Global Impression 61 endometrial thickness 61 eNO 61 serum urate levels 61 sustained ventricular tachycardia 61 adjunctive placebo 61 % CI #.#-#.# [008] 61 hematologic parameters 61 HBeAg negative patients 61 p = .# [001] 61 incontinence episodes 61 HRCT 61 CIMZIA TM certolizumab pegol 61 histological subtype 61 MoxDuo TM IR 61 Viral load 61 Main Outcome Measures 61 β blockers 61 femoral neck BMD 61 cirrhotic patients 61 transaminase elevations 61 postintervention 61 confidence interval #.#-#.# 61 TEAEs 61 specific antigen PSA 61 periprocedural 61 postoperative complication 61 RECIST Response Evaluation Criteria 61 prospectively defined 61 CI #.#-#.# [001] 61 SGPT 61 glomerular filtration 61 advanced adenoma 61 creatinine ratio 60 Scale Cognitive Subscale 60 VFQ 60 Likert scale 60 HBeAg seroconversion 60 psychiatric morbidity 60 carotid stenosis 60 SSRI SNRI 60 conditional logistic regression 60 ADHD Rating Scale 60 microalbumin 60 virologic response 60 PERMP 60 HbA1C levels 60 receiving ISENTRESS 60 Index CDAI score 60 Histologic 60 Erectile Function IIEF 60 serum parathyroid hormone 60 ± SEM 60 ALSFRS R 60 dyspnoea 60 PANSS scores 60 nonsignificant difference 60 hyperhomocysteinemia 60 Mania Rating Scale 60 adenoma recurrence 60 intraclass correlation coefficient 60 State Examination MMSE 60 mean baseline A1C 60 WOMAC scores 60 Heritability 60 SUVmax 60 Forced expiratory volume 60 #OHD 60 lymphocyte count 60 allele frequencies 60 Depression Rating Scale 60 P = .# 60 URTI 60 postoperative AF 60 Timed Walk 60 Wechsler Adult 60 T2DM 60 glycated hemoglobin levels 60 FDG PET imaging 60 plus methotrexate 60 covariate 60 cerebral oxygen saturation 60 RAPAFLO R 60 Key secondary endpoints 60 CPAP adherence 60 vitreous haze 60 ‰ ¥ 60 FFNS 60 Comorbidity 60 GERD symptom 60 affective psychosis 60 certolizumab 60 CC genotype 60 % CI #.#-#.# [004] 60 subclinical atherosclerosis 60 T2 lesions 60 non menstrual pelvic 60 PCWP 60 gadolinium enhancing lesions 60 OSAHS 60 neurologic impairment 60 achieved ACR# 60 serum ferritin 60 Kaplan Meier method 60 baseline A1C 60 Oswestry Disability Index 60 neutrophil counts 60 estimated glomerular filtration 60 pCR 60 plasma homocysteine 60 elevated LDH 60 EDSS scores 60 transcranial Doppler ultrasound 60 correlation coefficients 60 postprocedure 60 serum magnesium 60 nonsignificant 60 GH deficiency 60 knee osteoarthritis OA 60 primary aldosteronism 60 8mg/kg 60 Abnormal Involuntary Movement 60 serum IgG 60 aspartate aminotransferase AST 60 Response Evaluation Criteria 60 glycosylated hemoglobin HbA1c 60 Secondary efficacy endpoints 60 KRAS mutations occur 60 actigraphy 60 tertiles 60 atherogenic dyslipidemia 60 point Likert scale 60 albumin excretion 60 multivariable analysis 60 placebo p = 60 ≥ 60 subtests 60 microalbuminuria 60 CCyR 60 fasting plasma 60 virologic 60 overnight polysomnography 60 paraprotein 60 Respiratory Symptoms 60 psychopathological symptoms 59 QD dosing 59 methacholine 59 Acute Physiology 59 #.#ng/ml 59 COPD exacerbation 59 Symptom Checklist 59 PLMS 59 periprocedural MI 59 viral titers 59 subjective sleepiness 59 VaD 59 mmHg diastolic 59 clinically meaningful reductions 59 EDSS 59 cranial irradiation 59 AST ALT 59 Myocardial Infarction TIMI 59 inflammatory lesions 59 mcg doses 59 NSTEMI 59 psychiatric comorbidities 59 Incontinence Impact Questionnaire 59 dosing cohort 59 NSTE ACS 59 clinically meaningful improvements 59 CP CPPS 59 NIS LL 59 State Exam MMSE 59 abnormal cytology 59 nonvertebral fracture 59 troponin T 59 angiographically 59 Symptom Severity 59 adjunctive ABILIFY 59 poststroke 59 carotid IMT 59 MSLT 59 QTc 59 CHADS 59 PSADT 59 thromboembolic 59 statistically nonsignificant 59 urate lowering therapy 59 Serum creatinine 59 prostate cancer PCa 59 induced sputum 59 serum sodium levels 59 pulmonary capillary wedge 59 estimated GFR 59 racemic albuterol 59 Seattle Angina Questionnaire 59 serum lipid levels 59 platelet reactivity 59 statistically significant p = 59 serum estradiol 59 Evaluable 59 ertapenem 59 = #.#-#.# 59 pretest probability 59 CIBIC plus 59 pentoxifylline 59 secondary efficacy endpoint 59 calculated creatinine clearance 59 6MWD 59 accelerometry 59 Nocturia 59 subsyndromal 59 nausea photophobia 59 elevated bilirubin 59 multivariate regression analysis 59 T1DM 59 atherothrombotic disease 59 APTIVUS r 59 Thrombolysis 59 tapentadol ER 59 Child Behavior Checklist 59 nighttime awakenings 59 serum BDNF 59 antidiabetic medication 59 Kruskal Wallis test 59 F FDG PET 59 NHANES #-# 59 serum testosterone 59 FACIT 59 tipranavir ritonavir 59 diabetes mellitus DM 59 SRBD 59 Cardiorespiratory fitness 59 serum bilirubin 59 DAS# remission 59 preoperatively 59 convergent validity 59 aPTT 59 exploratory endpoints 59 microvessel density 59 serum IGF 59 mcg Albuferon 59 Multivariate logistic regression 59 Preoperatively 59 posttransplant 59 CANCIDAS 59 Poisson regression 59 hemoglobin A1c levels 59 biochemical relapse 59 seroconverted 59 neurodevelopmental impairment 59 hypoglycemic events 59 Endothelial function 59 PaO 2 59 mg kg dose 59 coronary artery calcification 59 seropositivity 59 #.#/#.# mmHg [001] 59 atorvastatin #mg 59 octreotide LAR 59 unpaired t 59 Hemoglobin A1c 59 undetectable HBV DNA 59 plasma leptin 59 μg kg 59 MBq 59 arterial thromboembolic events 58 flow mediated dilation 58 recurrent ischemia 58 bivariate analysis 58 CR nPR 58 ug dose 58 IQR 58 ipsilateral stroke 58 transaminase levels 58 glycated hemoglobin HbA1c 58 PHQ 9 58 prespecified secondary 58 mean ± SEM 58 receiving VICTRELIS 58 salivary flow 58 urodynamic parameters 58 TPV r 58 KCCQ 58 nonobese 58 mmol L. 58 virologic response EVR 58 tacrolimus ointment 58 mg TID 58 urinary iodine 58 UPDRS scores 58 multivariable analyzes 58 corrected QT interval 58 OGTT 58 desvenlafaxine succinate 58 demonstrated clinically meaningful 58 Likert 58 CONCERTA ® 58 Negative Symptoms 58 FDA defined valvulopathy 58 dose Iluvien 58 ROC curves 58 ARCOXIA 58 annualized relapse 58 mcg BID 58 myocardial infarctions 58 sUA 58 Postoperative complications 58 salmeterol fluticasone 58 NATRECOR R 58 creatinine clearance 58 inflammatory biomarkers 58 Depression Inventory 58 meta analytic 58 pyridostigmine 58 nonexposed 58 histologically confirmed 58 intraclass correlation coefficients 58 nadroparin 58 serum concentrations 58 XIENCE V PROMUS Stent 58 pharmacodynamic PD 58 manic hypomanic 58 adenotonsillectomy 58 metabolic syndrome MetS 58 atrophic gastritis 58 semiquantitative 58 insulin detemir 58 urine NGAL 58 flutamide 58 Cystic Fibrosis Questionnaire Revised 58 ASCUS 58 relapsed MM 58 Pain Rating Scale 58 covariance 58 microbiological eradication 58 fluticasone salmeterol 58 psychometric properties 58 exhaled nitric oxide 58 nondiabetic patients 58 endometrial hyperplasia 58 cEVR 58 Febrile neutropenia 58 x ULN 58 moderate renal impairment 58 anthropometric measures 58 baseline FEV 58 QTc prolongation 58 prodromal symptoms 58 Outcomes Study 58 serum homocysteine 58 BLLs 58 plasma folate 58 coronary calcification 58 serum triglyceride 58 LDL HDL 58 ± SD 58 Glomerular filtration rate 58 Subgroup analysis 58 leukocyte counts 58 serum potassium 58 somatic symptoms 58 Logistic regression 58 HbA 1C 58 peak VO2 58 nonvertebral fractures 58 euthymic patients 58 #μg [001] 58 brachial artery flow 58 nondepressed 58 doxorubicin docetaxel 58 CSBM 58 biochemical recurrence 58 Univariate analysis 58 arterial oxygen saturation 58 highly emetogenic 58 μg d 58 Kaplan Meier curves 58 urinary N telopeptide 58 Bonferroni correction 58 haematologic 58 cerebral oxygenation 58 PEPI 58 CIN2 + 58 Non inferiority 58 neurologic symptoms 58 overactive bladder symptoms 58 blood Phe levels 58 psychosocial functioning 58 Proteinuria 58 dyslipidaemia 58 binary restenosis 58 tissue oxygenation 58 extensive metabolizers 58 CIN3 58 β blocker 58 premorbid 58 HAM D# scores 58 enteroviral infection 58 8 OHdG 58 histologically proven 58 splenectomized patients 58 perioperative mortality 58 postop 58 treatment emergent AEs 58 Kaplan Meier estimates 58 Postoperatively 58 episodic migraine 58 Kaplan Meier analysis 58 BPRS PSS 58 experienced virologic failure 58 β = 58 cerebrovascular events 58 hypertensives 58 P ≤ 58 serum phosphorous 58 BPS IC 58 epoetin alpha 58 PSA kinetics 58 LVEF 58 International Prognostic Scoring 58 LV ejection fraction 58 mg/m2 dose 58 composite endpoint 58 T2 lesion volume 58 silent myocardial ischemia 58 rosuvastatin #mg 58 highest tertile 58 hypopneas 58 aged ≥ 58 thrombocytopenic 58 intact parathyroid hormone 58 subtest 58 prolonged QT interval 58 Hepatotoxicity 58 tumor histology 58 Renal dysfunction 58 acromegalic patients 58 virologic breakthrough 58 sputum eosinophils 58 genotypic resistance 58 serum prostate 58 Ashworth Scale 58 baseline PASI 58 ARIXTRA 58 PsA 58 symptomatic intracranial hemorrhage 57 suboptimal adherence 57 paricalcitol 57 scores TNSS 57 NHANES III 57 ACR# ACR# 57 artery occlusion 57 aminotransferase 57 HER2 expression 57 histologic subtype 57 solifenacin 57 NYHA 57 Suicidal ideation 57 HIV HCV coinfected 57 μmol L 57 ALT AST 57 oral prednisolone 57 aminotransferase levels 57 mcg linaclotide 57 partial remissions 57 microscopic hematuria 57 glomerular filtration rate 57 tertile 57 urinary cortisol 57 Knodell necroinflammatory score 57 pruritus itching 57 chi squared 57 clinicopathological 57 SCr 57 maximal treadmill 57 EBMT criteria 57 fasting glucose levels 57 hepatic enzyme 57 serum antibody 57 linaclotide treated 57 Multivariate analysis 57 achieving PASI 57 systolic BP 57 thyrotropin levels 57 daytime alertness 57 death reinfarction 57 rCBF 57 intima media thickness 57 bothersome symptom 57 venous thromboembolic disease 57 Replikin Count 57 mEq L 57 glycated hemoglobin 57 neurocognitive functioning 57 FDG-PET/CT 57 serum folate concentrations 57 dyssynchrony 57 p = NS 57 enthesitis 57 latent celiac disease 57 LUTS 57 ARB telmisartan 57 placebo p 57 chest radiographs 57 leucopenia 57 RLS symptoms 57 hemagglutination inhibition 57 depressive symptoms 57 polytherapy 57 nonfatal myocardial infarction 57 logistic regression models 57 haematological toxicity 57 CIMZIA ™ 57 del 5q MDS 57 ug kg 57 nmol l 57 emotional lability 57 Geriatric Depression 57 psychosocial variables 57 multivariable logistic regression 57 dose cohort 57 affective psychoses 57 TDF FTC 57 Hypotension 57 Solid Tumors criteria 57 ETDRS 57 MCyR 57 spontaneous bowel movements 57 prospectively enrolled 57 pretreatment serum 57 serum phosphate 57 microg 57 extrapyramidal side 57 NNRTI resistance 57 Descriptive statistics 57 chi ^ sup 57 μg dL 57 rheumatoid factor 57 CSBMs 57 intramuscular dose 57 mucosal healing 57 hypoglycaemic episodes 57 Platelet counts 57 symptomatology 57 mL kg 57 Aggrenox ® 57 ECLS 57 FEV ^ sub 57 artery stenosis 57 severe neutropenia 57 Coronary artery calcium 57 AUA BPH Symptom Score 57 complete cytogenetic response 57 neurodevelopmental outcome 57 multivariate analyzes 57 phosphorylated tau 57 mg kg cohorts 57 suicide attempters 57 budesonide pMDI 57 TT genotype 57 FDG PET scans 57 HPA axis suppression 57 CI #.#-#.# [002] 57 STRIDE PD 57 invasive aspergillosis 57 hemodynamic variables 57 D dimer 57 Logistic regression analysis 57 cytologic 57 p ≤ 57 hemodynamic measurements 57 bepotastine besilate nasal spray 57 hypophosphatemia 57 CRp 57 ischemic lesions 57 ALT flares 57 euthyroid 57 hypercalciuria 57 anti JCV antibodies 57 nerve conduction velocity 57 log# copies mL 57 INVEGA ® 57 serum selenium 57 hemoglobin A1C 57 SSRI citalopram 57 intravenous tPA 57 chronic prostatitis 57 QALE 57 reinfarction 57 blood Phe 57 covariance ANCOVA 57 diastolic hypertension 57 beta blocker therapy 57 AUC0 57 apolipoprotein B 57 MDRD 57 plus medroxyprogesterone acetate 57 nocturnal awakenings 57 FDG uptake 57 Subscale 57 Flu Cy 57 homocysteine concentrations 57 HBeAg positive patients 57 #q# deletion syndrome 57 reactogenicity 57 overt nephropathy 57 elevated triglyceride levels 57 thromboembolism 57 receiving highly emetogenic 57 urinary albumin excretion 57 antioxidant supplementation 57 BARACLUDE ® 57 lymphocyte counts 57 SpCO 57 log# reduction 57 glycosylated hemoglobin 57 hepatic enzymes 57 oral glucose tolerance 57 liver transplant recipients 57 endoscopic remission 57 syndromal 57 laboratory abnormalities 57 NOAEL 57 elevated creatinine 57 confidence interval CI 57 ROC curve 57 serum sodium 57 urinary sodium excretion 57 conjugated equine estrogen 57 cTnT 57 hematological parameters 57 ALT elevation 57 r2 = 57 cognitive affective 57 PRADAXA #mg 57 hematopoietic cancers 57 Functioning GAF 57 dysuria 57 bioavailable testosterone 57 Venous thromboembolism 57 HbA1c levels 57 nasal polyposis 57 bronchial responsiveness 57 fasting plasma glucose FPG 57 retest reliability 57 Mini Mental 57 ejection fractions 57 QTc interval 57 ropivacaine 57 decrements 57 QRS duration 57 multiple linear regression 57 DLTs 57 advanced neoplasia 57 androgen suppression 57 arterial elasticity 57 BENICAR HCT 57 prostate cancer CaP 57 ß = 57 triiodothyronine 56 -#.# mg dL [001] 56 premenopause 56 PREZISTA r arm 56 abdominal adiposity 56 polyp recurrence 56 ATACAND 56 pharmacokinetics PK 56 spine BMD 56 mL/min/#.# m 2 56 pT3 56 aminotransferases 56 lactate dehydrogenase LDH 56 function subscale 56 total cholesterol triglycerides 56 Dietary intake 56 BALF 56 mmol l 56 hypoglycemic episodes 56 serum lipid 56 6MWT 56 cerebrovascular accidents 56 retrospective cohort 56 interobserver agreement 56 triacylglycerol concentrations 56 Beck Anxiety Inventory 56 NPH insulin 56 rFVIIa 56 statistically significant p 56 logistic regression 56 airway hyperresponsiveness 56 pairwise comparisons 56 anagrelide 56 perimenopausal women 56 ventricular repolarization 56 urinary symptoms 56 ragweed allergic 56 postinjury 56 rituximab monotherapy 56 paresthesias 56 hydroxyvitamin D levels 56 isoprostane 56 pericardial effusion 56 Endocrine Therapy 56 eszopiclone 56 comorbid anxiety 56 clomipramine 56 dyspareunia 56 nontraumatic 56 Mean Symptom Complex 56 multivariable adjustment 56 LRTI 56 mammographic density 56 NATRECOR ® 56 cognitive domains 56 lactate dehydrogenase 56 fasting triglycerides 56 systolic dysfunction 56 receiving APTIVUS r 56 incidence ≥ 56 NMIBC 56 conjunctival hyperemia 56 Univariate